jamunjar-logo
whatsapp
cartmembermenu
Search for
"test & packages"
"physiotherapy"
"heart"
"lungs"
"diabetes"
"kidney"
"liver"
"cancer"
"thyroid"
"bones"
"fever"
"vitamin"
"iron"
"HTN"

Melanoma - Medium Biopsy 1-3 cm

Biopsy
image

Report in 288Hrs

image

At Home

nofastingrequire

No Fasting Required

Details

Skin biopsy for suspected melanoma.

₹370₹529

30% OFF

Melanoma - Medium Biopsy 1-3 cm

  • Why is it done?
    • To obtain tissue sample from suspicious skin lesions measuring 1-3 cm in diameter for histopathological examination and melanoma diagnosis
    • To evaluate skin lesions with concerning features such as asymmetry, irregular borders, color variation, or diameter >6 mm (ABCDE criteria)
    • To determine histological type, depth of invasion, and stage of melanoma for treatment planning
    • To assess for dysplasia or atypical melanocytic proliferation in pigmented lesions
    • Typically performed when dermatoscopy or clinical examination suggests possible melanoma in medium-sized lesions
  • Normal Range
    • Normal Result: Benign skin lesion (e.g., nevus, seborrheic keratosis, other non-malignant conditions)
    • Negative Result: No evidence of melanoma or other malignancy; normal benign pathology
    • Measurement Unit: Histopathological examination reported as microscopic tissue analysis with interpretation
    • Abnormal Result: Presence of melanoma (in situ or invasive), atypical nevus, or dysplastic changes
    • Report includes pathologist description, Clark level, Breslow thickness, mitotic rate, ulceration status, and margins
  • Interpretation
    • Melanoma Diagnosis: Presence of malignant melanocytic proliferation requires staging and further workup; prognosis depends on depth and other features
    • Breslow Thickness: <0.8 mm (Stage IA) indicates lowest risk; >4 mm indicates higher risk with metastatic potential
    • Clark Level: Measures depth of invasion (I-V); higher levels indicate deeper invasion and worse prognosis
    • Mitotic Rate: Higher mitotic rate (>1 per mm²) indicates more aggressive tumor and worse prognosis
    • Ulceration: Present ulceration indicates Stage IB or higher disease with significantly increased recurrence risk
    • Margins: Clear margins >required distance indicate complete excision; involved margins may require re-excision
    • Atypical Nevus: Shows dysplastic features but does not meet criteria for melanoma; associated with increased melanoma risk
    • Benign Lesion: No further melanoma-related treatment needed; routine follow-up continues based on patient risk factors
  • Associated Organs
    • Primary: Skin (integumentary system); melanocytes in epidermis and dermis
    • Secondary/Metastatic Sites: Lymph nodes, lungs, brain, liver, bone, and distant skin sites in advanced disease
    • Melanoma is an aggressive malignancy with high metastatic potential, particularly when thickness >1 mm or ulceration present
    • Associated conditions: Dysplastic nevus syndrome, familial melanoma, xeroderma pigmentosum, and increased UV exposure history
    • Risk factors: Fair skin, multiple nevi, sunburn history, immunosuppression, and genetic mutations (BRAF, NRAS, NF1, KIT)
    • Complications of melanoma: Regional lymph node involvement, systemic metastasis, reduced survival, and significant morbidity/mortality
  • Follow-up Tests
    • If Melanoma Confirmed: Sentinel lymph node biopsy for staging (if Stage IB or higher); wide local re-excision; imaging studies (CT, MRI, PET-CT) for metastatic disease evaluation
    • Genetic Testing: BRAF V600E mutation testing; microsatellite testing; immunohistochemistry for S100, HMB-45, Melan-A
    • Staging Studies: Chest X-ray, abdominal/pelvic imaging, brain MRI (if high-risk features); lymphoscintigraphy for sentinel node identification
    • Monitoring Program: Regular clinical skin examination every 3-6 months; total body photography; dermoscopy surveillance for new suspicious lesions
    • Additional Imaging: Periodic ultrasound of regional lymph nodes; baseline and surveillance imaging based on stage and risk stratification
    • Treatment Planning Tests: Baseline tumor markers; lactate dehydrogenase (LDH); liver function tests; renal function prior to immunotherapy or targeted therapy
    • If Benign Result: Routine skin self-examination; annual dermatologic exam; no further melanoma-specific workup required unless high-risk features present
  • Fasting Required?
    • Fasting: No - fasting is not required for this skin biopsy procedure
    • Pre-procedure Preparation: Skin area should be clean; avoid sunscreen, makeup, or lotions on biopsy site for 24 hours prior if possible; wear loose clothing
    • Medications to Continue: Continue all regular medications; inform provider of anticoagulants (warfarin, dabigatran) or antiplatelet agents (aspirin, clopidogrel)
    • Medications to Avoid: May need to hold anticoagulants/antiplatelets 3-7 days before procedure per provider instructions; avoid NSAIDs 5-7 days prior if possible
    • Topical Preparations: Avoid retinoids, vitamin C serums, benzoyl peroxide on biopsy area for 48 hours prior; do not use perfumes or colognes on biopsy site
    • Day of Procedure: Eat normally; take regular medications with water; no special restrictions; bring photo ID and insurance information
    • Post-procedure Care: Keep wound clean and dry; avoid swimming/soaking for 7-10 days; follow specific wound care instructions provided; avoid strenuous activity 24-48 hours

How our test process works!

customers
customers